ロード中...
Combination of acamprosate and baclofen (PXT864) as a potential new therapy for amyotrophic lateral sclerosis
There is currently no therapy impacting the course of amyotrophic lateral sclerosis (ALS). The only approved treatments are riluzole and edaravone, but their efficacy is modest and short‐lasting, highlighting the need for innovative therapies. We previously demonstrated the ability of PXT864, a comb...
保存先:
| 出版年: | J Neurosci Res |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7693228/ https://ncbi.nlm.nih.gov/pubmed/32815196 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jnr.24714 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|